3 completed, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow codrituzumab: new trials by email Literature Review of codrituzumab trials Research Report on codrituzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment Codrituzumab - Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2021-06-09 | 2026-10-26 |
| A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Placebo, GC33 - Carcinoma, Hepatocellular | Phase 2 | Completed | Hoffmann-La Roche | 185 | 2012-02-02 | 2020-04-03 |
| Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) GC33(RO5137382), Sorafenib - Hepatocellular Carcinoma | Phase 1 | Completed | Chugai Pharmaceutical | 42 | 2009-09-01 | 2014-10-03 |
| A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) GC33 - Advanced or Metastatic HCC | Phase 1 | Completed | Chugai Pharmaceutical | 27 | 2008-09-01 | 2012-10-17 |
Carcinoma, Hepatocellular (2) · Hepatoblastoma (1) · Recurrence (1) · Simpson-Golabi-Behmel syndrome (1)
Chugai Pharmaceutical (2) · Hoffmann-La Roche (1) · Memorial Sloan Kettering Cancer Center (1)
United States (4) · Taiwan (2) · Belgium (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Japan (1) · New Zealand (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Michael Ortiz, MD (1) · Toshihiko Ohtomo (1)